Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs TransMedics Group Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.41 (market cap $41.13B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 15× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and TransMedics Group Inc for 24 Days on average.
| IEF | TMDX | |
|---|---|---|
Market Cap | $41.13B | $2.74B |
Volume | 10,340,382 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $150.42 |
52-Week Low | $88.92 | $61.99 |
Typical Hold Time | 108 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
